Special issue review compiles real-world evidence for GLP-1 drug use, bridging the gap between clinical trial results and everyday clinical practice outcomes.
Key findingSpecial issue review compiles real-world evidence for GLP-1 drug use, bridging the gap between clini
What the researchers found
Special issue review compiles real-world evidence for GLP-1 drug use, bridging the gap between clinical trial results and everyday clinical practice outcomes.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Specific weight loss percentages not detailed in abstract; results described as surpassing existing approved treatments in earlier phase trials.
How the study worked
In publication.
Who was studied
Adults with obesity
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.
Drugs in context, 14
Citation
Anderson, Sarah L. (2025). Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.. Drugs in context, 14. https://doi.org/10.7573/dic.2025-4-8